

*This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell the FCC Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.*

9 May 2022

<b>To,</b> <b>Dy. General Manager</b> <b>Department of Corporate Services,</b> <b>BSE Ltd.</b> <b>Phiroze Jeejeebhoy Towers</b> <b>Dalal Street, Fort, Mumbai – 400 001</b>  <b>Ref: Scrip Code: 532296</b>	<b>To,</b> <b>The Manager – Listing</b> <b>National Stock Exchange of India Ltd.,</b> <b>Plot No. C/1, G Block,</b> <b>Bandra Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051</b>  <b>Ref: Scrip Name: GLENMARK</b>
--	---


Dear Sirs,

**Re: Intimation of buyback by Glenmark Pharmaceuticals Limited (the "Company") in respect of the US\$ 200,000,000 2.00% Resetable Onward Starting Equity-Linked Securities due 2022 (the "FCC Bonds")**

With respect to the above subject, we have made an announcement to the Singapore Exchange Securities Trading Limited dated May 9, 2022. Please find enclosed herewith a copy of the same as Annexure A.

You are requested to take the same on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,  
Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

  
Harish Kuber  
**Company Secretary and Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

9 May 2022

To:

**SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED**  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589

**GLENMARK PHARMACEUTICALS LIMITED (THE “ISSUER”)**

U.S. \$200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022  
ISIN: XS1426780125  
Common Code: 142678012  
(the “Bonds”)

**NOTICE OF REDEMPTION**

Pursuant to, and in accordance with, the terms of the trust deed dated 28 June 2016 (the “**Trust Deed**”) constituting the Bonds, the Issuer has redeemed the Notes in full on 9 May 2022 (the “**Redemption Date**”) pursuant to Condition 8.2 (*Redemption at the option of the Issuer*) of the terms and conditions of the Bonds.

The Bonds will be cancelled as of the Redemption Date and will be delisted from the Singapore Exchange Securities Trading Limited.

This announcement is for informational purposes only and shall not constitute an offer to purchase the Bonds.

9 May 2022

THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR BROKER, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER.

*This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell, the Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.*

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)